EGFR and cancer: A study using cytological in vitro and in vivo experiments in tumor-bearing mice found that a combination of the EGFR monoclonal antibody (mAb) cetuximab and afatinib inhibited the growth of cells or transplanted tumors carrying EGFR exon 20 partial insertion mutations and promoted apoptosis of cancer cells [40].